3009849-06-0
Chemical Structure
BJG-05-039
- CAS No.: 3009849-06-0
- Formula:C41H44ClF3N8O5
- Molecular Weight:821.29
IUPAC Name: (3-bromo-1-methyl-1H-pyrazol-4-yl)methanol
InChIKey: UZPKWEBZEBROEX-AYTRYJACSA-N
SMILES: FC(F)CN1C2=C(C=C(Cl)C=C2)C(N[C@H]3CCN(C(NCCCCCCCCNC4=CC=CC(C(N5C6CCC(NC6=O)=O)=O)=C4C5=O)=O)C3)=NC7=CC(F)=CC=C17
Biological Activity: BJG-05-039 is an inhibitor targeting PAK1, with an IC50 of 233 nM against human PAK1. BJG-05-039 induces the selective degradation of PAK1 and inhibits its kinase activity by conjugating NVS-PAK1-1 (HY-100519) with Lenalidomide (HY-A0003) to recruit Cereblon. BJG-05-039 can be used in research related to breast cancer and ovarian cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BJG-05-039 | 98.06% | BJG-05-039 is an inhibitor targeting PAK1, with an IC50 of 233 nM against human PAK1. BJG-05-039 induces the selective degradation of PAK1 and inhibits its kinase activity by conjugating NVS-PAK1-1 (HY-100519) with Lenalidomide (HY-A0003) to recruit Cereblon. BJG-05-039 can be used in research related to breast cancer and ovarian cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Chow HY, et al. Development and Utility of a PAK1-Selective Degrader. Journal of medicinal chemistry. 2022 Dec 08;65(23):15627-15641. [Content Brief]
- [2]. Johns DM, et al. Identification of a p21-activated kinase 1 (PAK1) inhibitor with 10-fold selectivity against PAK2. Bioorganic & medicinal chemistry letters. 2025 Nov 01;127:130307. [Content Brief]
